Sorry!! The article you are trying to read is not available now.
Vivus Stock Soars As Aetna Adds Qsymia To Coverage
Biotech Vivus (VVUS) popped nearly 13% early Wednesday after insurer Aetna (AET) revised its weight-loss-treatment policy to include Vivus' obesity drug Qsymia. In a revision issued Tuesday to its clinical policy, Aetna outlined the conditions to be met for obesity-treatment coverage and listed the approved treatments, now including Qsymia and Arena Pharmaceuticals (ARNA) Belviq, both of which have been cleared by the FDA since the last review of
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

WHAT'S POPULAR IN THE VILLE